Literature DB >> 7493895

Clinical efficacy of increased dosages of milbemycin oxime for treatment of generalized demodicosis in adult dogs.

W H Miller1, D W Scott, S M Cayatte, R G Buerger, M S Bagladi.   

Abstract

OBJECTIVE: To determine the efficacy of increased dosages of milbemycin oxime in the treatment of generalized demodicosis.
DESIGN: Prospective clinical trial. ANIMALS: 26 adult dogs with chronic generalized demodicosis. PROCEDURE: In phase 1, milbemycin was administered daily to 13 dogs at an approximate mean dosage of 1 mg/kg of body weight (PO) until 30 days after skin scrapings failed to detect mites. If the mite count had not decreased by 25% from the prior month's examination, the drug dosage was increased to approximately 2 mg/kg. Treatment was considered a failure if the mite count had not changed on 2 successive examinations. In phase 2 involving 13 other dogs, an approximate mean dosage of 2 mg/kg was used. If mite counts had not been reduced to 0 by 180 days, treatment was considered to have failed.
RESULTS: In phase 1, when milbemycin was administered at the initial low dosage, 6 dogs were considered to have been cleared of mites. One of these relapsed 2 months after discontinuation of treatment. For the 7 dogs not cleared of mites, the dosage was doubled. Two of these were never cleared of mites. In phase 2, 12 of 13 dogs were cleared of mites after 60 to 180 days of treatment. CLINICAL IMPLICATIONS: High-dose milbemycin was effective in the treatment of generalized demodicosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493895

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  6 in total

1.  Treatment of canine scabies with milbemycin oxime.

Authors:  W H Miller; C de Jaham; D W Scott; S M Cayatte; M S Bagladi; R G Buerger
Journal:  Can Vet J       Date:  1996-04       Impact factor: 1.008

2.  The main factors influencing canine demodicosis treatment outcome and determination of optimal therapy.

Authors:  Milica Arsenović; Lato Pezo; Nebojša Vasić; Rodoljub Ćirić; Milan Stefanović
Journal:  Parasitol Res       Date:  2015-05-28       Impact factor: 2.289

3.  Comparative efficacy and safety of two treatment regimens with a topically applied combination of imidacloprid and moxidectin (Advocate) against generalised demodicosis in dogs.

Authors:  Josephus J Fourie; Petrus C Delport; Leon J Fourie; Josef Heine; Ivan G Horak; Klemens J Krieger
Journal:  Parasitol Res       Date:  2009-08       Impact factor: 2.289

4.  Efficacy of lotilaner (Credelio™), a novel oral isoxazoline against naturally occurring mange mite infestations in dogs caused by Demodex spp.

Authors:  Daniel E Snyder; Scott Wiseman; Julian E Liebenberg
Journal:  Parasit Vectors       Date:  2017-11-01       Impact factor: 3.876

5.  Efficacy of Amitraz plus Metaflumizone for the treatment of canine demodicosis associated with Malassezia pachydermatis.

Authors:  Viviana D Tarallo; Riccardo P Lia; Mariateresa Sasanelli; Claudia Cafarchia; Domenico Otranto
Journal:  Parasit Vectors       Date:  2009-03-05       Impact factor: 3.876

6.  Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto® 1-Month) is effective for treatment of canine generalized demodicosis.

Authors:  Nadja Rohdich; Leon Meyer; Frank Guerino
Journal:  Parasit Vectors       Date:  2022-03-12       Impact factor: 4.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.